0001567619-19-006615.txt : 20190311
0001567619-19-006615.hdr.sgml : 20190311
20190311191054
ACCESSION NUMBER: 0001567619-19-006615
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190307
FILED AS OF DATE: 20190311
DATE AS OF CHANGE: 20190311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANAN MICHAEL F
CENTRAL INDEX KEY: 0001461953
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 19673585
MAIL ADDRESS:
STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4
1
doc1.xml
FORM 4
X0306
4
2019-03-07
0
0001012477
AVADEL PHARMACEUTICALS PLC
FLML
0001461953
KANAN MICHAEL F
BLOCK 10-1, BLANCHARDSTOWN
CORPORATE PARK, BALLYCOOLIN
DUBLIN
L2
15
IRELAND
0
1
0
0
See Remarks
ADSs
2019-03-07
4
A
0
18000
0
A
50538
D
Stock Option (right to buy)
16.21
2025-10-28
ADSs
100000
100000
D
Stock Option (right to buy)
10.4
2026-12-14
ADSs
100000
100000
D
Stock Option (right to buy)
8.95
2027-12-12
ADSs
80000
80000
D
Stock Option (right to buy)
1.85
2019-03-07
4
A
0
80000
1.85
A
2029-03-07
ADSs
80000
80000
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
Includes (a) 18,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 12/14/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 8,429 ADSs on December 14, 2018; (b) 18,000 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 12,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 6,000 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); (c) 3,000 ADSs acquired under the issuer's 2017 Employee Share Purchase Plan on 1/8/2019; and [continued in footnote 3 below]
(d) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary).
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 10/28/2015 grant date.
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date.
Sr. VP, Chief Financial Officer.
/s/ Phillandas T. Thompson, as attorney-in-fact for Michael F. Kanan
2019-03-11